Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener klinische Wochenschrift 11-12/2018

24.05.2018 | original article

Phenotypes of COPD in an Austrian population

National data from the POPE study

verfasst von: Gabriele Reiger, Ralf Zwick, Bernd Lamprecht, Christian Kähler, Otto Chris Burghuber, MD, FCCP Assoc. Professor Arschang Valipour

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 11-12/2018

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Chronic obstructive pulmonary disease (COPD) represents a major global health problem; however, there are no data regarding clinical phenotypes of these patients in Austria.

Methods

This was an analysis from the Austrian cohort of the cross-sectional Phenotypes of COPD in Central and Eastern Europe (POPE) study, which was offered to patients with stable COPD in a real-life setting. Patients were recruited at 5 different outpatient facilities in 3 different provinces in Austria. All consecutive patients aged ≥40 years with a diagnosis of COPD confirmed by a post-bronchodilator forced expired volume in 1 s/forced vital capacity (FEV1/FVC) ratio <0.7 during a stable state (≥4 weeks without exacerbation or worsening of any relevant comorbidities) were considered eligible. The primary aim of this study was to assess the prevalence of phenotypes according to predefined criteria. Secondary aims included analyses of differences in patient characteristics, symptom load, comorbidities, and pharmacological treatment.

Results

Among 283 patients fulfilling the inclusion criteria, 49.5% were considered non-exacerbators, 21.6% were classified as exacerbators with chronic bronchitis, 21.2% exacerbators without chronic bronchitis, and 7.8% were patients with an asthma-COPD overlap. Exacerbators had significantly higher prevalence of symptoms, lower lung function and exercise capacity, and a higher prevalence of comorbidities, such as heart failure and depression, compared with the other patient phenotypes. A large majority of patients with stable COPD in this cohort received inhaled triple therapy, irrespective of exacerbation history.

Conclusions

There were significant differences in COPD outcome measures between predefined phenotypes of COPD in this study. The majority of patients with stable COPD in this Austrian population were not treated according to current COPD guidelines. While non-exacerbators appear to have been overtreated, patients with an asthma-COPD overlap appear to have been undertreated.
Literatur
1.
Zurück zum Zitat Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2016. http://​goldcopd.​org/​ (Created 1 Feb 2016). Accessed 26 May 2016. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2016. http://​goldcopd.​org/​ (Created 1 Feb 2016). Accessed 26 May 2016.
2.
Zurück zum Zitat Weiss G, Steinacher I, Lamprecht B, Schirnhofer L, Kaiser B, Sönnichsen A, Studnicka M. Detection of chronic obstructive pulmonary disease in primary care in Salzburg, Austria: findings from the real world. Respiration. 2014;87(2):136–43. CrossRef Weiss G, Steinacher I, Lamprecht B, Schirnhofer L, Kaiser B, Sönnichsen A, Studnicka M. Detection of chronic obstructive pulmonary disease in primary care in Salzburg, Austria: findings from the real world. Respiration. 2014;87(2):136–43. CrossRef
3.
Zurück zum Zitat Firlei N, Lamprecht B, Schirnhofer L, Kaiser B, Studnicka M. The prevalence of COPD in Austria—the expected change over the next decade. Wien Klin Wochenschr. 2007;119(17–18):513–8. CrossRef Firlei N, Lamprecht B, Schirnhofer L, Kaiser B, Studnicka M. The prevalence of COPD in Austria—the expected change over the next decade. Wien Klin Wochenschr. 2007;119(17–18):513–8. CrossRef
4.
Zurück zum Zitat Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182:598–604. CrossRef Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182:598–604. CrossRef
5.
Zurück zum Zitat Zbozinkova Z, Barczyk A, Tkacova R, Valipour A, Tudoric N, Zykov K, Somfay A, Miravitlles M, Koblizek V. POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe. Int J Chron Obstruct Pulmon Dis. 2016;11:611–22. PubMedPubMedCentral Zbozinkova Z, Barczyk A, Tkacova R, Valipour A, Tudoric N, Zykov K, Somfay A, Miravitlles M, Koblizek V. POPE study: rationale and methodology of a study to phenotype patients with COPD in Central and Eastern Europe. Int J Chron Obstruct Pulmon Dis. 2016;11:611–22. PubMedPubMedCentral
6.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. CrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. CrossRef
7.
Zurück zum Zitat Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38. CrossRef Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26:319–38. CrossRef
8.
Zurück zum Zitat Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68. CrossRef Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68. CrossRef
9.
Zurück zum Zitat Roca J, Burgos F, Sunyer J, Saez M, Chinn S, Antó JM, Rodríguez-Roisin R, Quanjer PH, Nowak D, Burney P, Group of the European Community Respiratory Health Survey. References values for forced spirometry. Eur Respir J. 1998;11:1354–62. CrossRef Roca J, Burgos F, Sunyer J, Saez M, Chinn S, Antó JM, Rodríguez-Roisin R, Quanjer PH, Nowak D, Burney P, Group of the European Community Respiratory Health Survey. References values for forced spirometry. Eur Respir J. 1998;11:1354–62. CrossRef
10.
Zurück zum Zitat Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis. 2016;11:3–12. PubMedPubMedCentral Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV1. Int J Chron Obstruct Pulmon Dis. 2016;11:3–12. PubMedPubMedCentral
11.
Zurück zum Zitat Agustí A, Celli B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. Eur Respir J. 2011;38:749–51. CrossRef Agustí A, Celli B. Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. Eur Respir J. 2011;38:749–51. CrossRef
12.
Zurück zum Zitat Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H, Sandström T, Śliwiński P, Zatloukal J, Blasi F. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47:625–37. CrossRef Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H, Sandström T, Śliwiński P, Zatloukal J, Blasi F. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47:625–37. CrossRef
13.
Zurück zum Zitat Koblizek V, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K, Tudoric N, Kostov K, Zbozinkova Z, Svancara J, Sorli J, Krams A, Miravitlles M, Valipour A. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017;49(5):1601446. CrossRef Koblizek V, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K, Tudoric N, Kostov K, Zbozinkova Z, Svancara J, Sorli J, Krams A, Miravitlles M, Valipour A. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J. 2017;49(5):1601446. CrossRef
14.
Zurück zum Zitat Cosio BG, Soriano JB, López-Campos JL, Calle M, Soler JJ, de-Torres JP, Marín JM, Martínez C, de Lucas P, Mir I, Peces-Barba G, Feu-Collado N, Solanes I, Alfageme I. CHAIN study. Distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN cohort. PLoS ONE. 2016;11(9):e160770. CrossRef Cosio BG, Soriano JB, López-Campos JL, Calle M, Soler JJ, de-Torres JP, Marín JM, Martínez C, de Lucas P, Mir I, Peces-Barba G, Feu-Collado N, Solanes I, Alfageme I. CHAIN study. Distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN cohort. PLoS ONE. 2016;11(9):e160770. CrossRef
15.
Zurück zum Zitat Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757–64. CrossRef Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012;7:757–64. CrossRef
16.
Zurück zum Zitat Lindberg A, Sawalha S, Hedman L, Larsson LG, Lundbäck B, Rönmark E. Subjects with COPD and productive cough have an increased risk for exacerbations and death. Respir Med. 2015;109:88–95. CrossRef Lindberg A, Sawalha S, Hedman L, Larsson LG, Lundbäck B, Rönmark E. Subjects with COPD and productive cough have an increased risk for exacerbations and death. Respir Med. 2015;109:88–95. CrossRef
17.
Zurück zum Zitat Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–66. CrossRef Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–66. CrossRef
18.
Zurück zum Zitat Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, Agusti A, FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–62. CrossRef Wedzicha JA, Singh D, Vestbo J, Paggiaro PL, Jones PW, Bonnet-Gonod F, Cohuet G, Corradi M, Vezzoli S, Petruzzelli S, Agusti A, FORWARD Investigators. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–62. CrossRef
20.
Zurück zum Zitat Price DB, Baker CL, Zou KH, Higgins VS, Bailey JT, Pike JS. Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification. Int J Chron Obstruct Pulmon Dis. 2014;9:551–61. PubMedPubMedCentral Price DB, Baker CL, Zou KH, Higgins VS, Bailey JT, Pike JS. Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification. Int J Chron Obstruct Pulmon Dis. 2014;9:551–61. PubMedPubMedCentral
21.
Zurück zum Zitat Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106:989–97. CrossRef Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106:989–97. CrossRef
22.
Zurück zum Zitat Davis KJ, Landis SH, Oh YM, Mannino DM, Han MK, van der Molen T, Aisanov Z, Menezes AM, Ichinose M, Muellerova H. Continuing to confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countries. Int J Chron Obstruct Pulmon Dis. 2014;10:39–55. PubMedPubMedCentral Davis KJ, Landis SH, Oh YM, Mannino DM, Han MK, van der Molen T, Aisanov Z, Menezes AM, Ichinose M, Muellerova H. Continuing to confront COPD International Physician Survey: physician knowledge and application of COPD management guidelines in 12 countries. Int J Chron Obstruct Pulmon Dis. 2014;10:39–55. PubMedPubMedCentral
23.
Zurück zum Zitat Salinas GD, Williamson JC, Kalhan R, Thomashow B, Scheckermann JL, Walsh J, Abdolrasulnia M, Foster JA. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis. 2011;6:171–9. CrossRef Salinas GD, Williamson JC, Kalhan R, Thomashow B, Scheckermann JL, Walsh J, Abdolrasulnia M, Foster JA. Barriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physicians. Int J Chron Obstruct Pulmon Dis. 2011;6:171–9. CrossRef
24.
Zurück zum Zitat Menezes AM, Landis SH, Han MK, Muellerova H, Aisanov Z, van der Molen T, Oh YM, Ichinose M, Mannino DM, Davis KJ. Continuing to confront COPD International Surveys: comparison of patient and physician perceptions about COPD risk and management. Int J Chron Obstruct Pulmon Dis. 2015;10:159–72. PubMedPubMedCentral Menezes AM, Landis SH, Han MK, Muellerova H, Aisanov Z, van der Molen T, Oh YM, Ichinose M, Mannino DM, Davis KJ. Continuing to confront COPD International Surveys: comparison of patient and physician perceptions about COPD risk and management. Int J Chron Obstruct Pulmon Dis. 2015;10:159–72. PubMedPubMedCentral
25.
Zurück zum Zitat Miravitlles M, Andreu I, Romero Y, Sitjar S, Altés A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract. 2012;62:e68–e75. CrossRef Miravitlles M, Andreu I, Romero Y, Sitjar S, Altés A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract. 2012;62:e68–e75. CrossRef
26.
Zurück zum Zitat Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2017. http://​goldcopd.​org/​. Accessed 8 Jan 2017. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2017. http://​goldcopd.​org/​. Accessed 8 Jan 2017.
27.
Zurück zum Zitat Tudoric N, Koblizek V, Miravitlles M, Valipour A, Milenkovic B, Barczyk A, Somfay A, Zykov K, Kostov K, Zbozinkova Z, Svoboda M, Sorli J, Krams A, Tkacova R. GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur Respir J. 2017;49(4):1602518. CrossRef Tudoric N, Koblizek V, Miravitlles M, Valipour A, Milenkovic B, Barczyk A, Somfay A, Zykov K, Kostov K, Zbozinkova Z, Svoboda M, Sorli J, Krams A, Tkacova R. GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur Respir J. 2017;49(4):1602518. CrossRef
Metadaten
Titel
Phenotypes of COPD in an Austrian population
National data from the POPE study
verfasst von
Gabriele Reiger
Ralf Zwick
Bernd Lamprecht
Christian Kähler
Otto Chris Burghuber
MD, FCCP Assoc. Professor Arschang Valipour
Publikationsdatum
24.05.2018
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 11-12/2018
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-018-1347-7